BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21358107)

  • 1. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease.
    Tsimafeyeu I; Demidov L
    J Cancer Res Ther; 2010; 6(4):575-7. PubMed ID: 21358107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
    Tsimafeyeu I
    J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
    Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
    Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
    Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
    Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
    Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma.
    Locatelli MC; Miedico A; D'Antona A; Longo G; Maggioni M; Maggioni A; Tombolini P; Tabiadon D
    Tumori; 2010; 96(3):478-82. PubMed ID: 20845812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
    Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
    Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
    J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
    Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.
    Stewart GD; Powles T; Van Neste C; Meynert A; O'Mahony F; Laird A; Deforce D; Van Nieuwerburgh F; Trooskens G; Van Criekinge W; De Meyer T; Harrison DJ
    Oncotarget; 2016 May; 7(18):25241-50. PubMed ID: 27029034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib therapy in renal cell carcinoma.
    O'Brien MF; Russo P; Motzer RJ
    BJU Int; 2008 Jun; 101(11):1339-42. PubMed ID: 18284408
    [No Abstract]   [Full Text] [Related]  

  • 13. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
    Rini BI; Shaw V; Rosenberg JE; Kim ST; Chen I
    Clin Genitourin Cancer; 2006 Dec; 5(3):232-4. PubMed ID: 17239278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
    Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
    BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
    Choueiri TK; Xie W; Kollmannsberger C; North S; Knox JJ; Lampard JG; McDermott DF; Rini BI; Heng DY
    J Urol; 2011 Jan; 185(1):60-6. PubMed ID: 21074201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sarcomatoid renal cell carcinoma with von Hippel-Lindau disease: a case report].
    Minagawa T; Nishizawa S; Kamigaito M; Nakayama T; Okaneya T
    Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):723-6. PubMed ID: 17682453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
    Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI
    J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
    Bex A; van der Veldt AA; Blank C; van den Eertwegh AJ; Boven E; Horenblas S; Haanen J
    World J Urol; 2009 Aug; 27(4):533-9. PubMed ID: 19145434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
    Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
    Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-surgical targeted molecular therapy in renal cell carcinoma.
    Margulis V; Wood CG
    BJU Int; 2009 Jan; 103(2):150-3. PubMed ID: 19007359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.